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Abstract One of the issues to be resolved in phenylketon-
uria is whether patients with mild hyperphenylalaninemia
needtreatment,orinotherwords,inwhatpatientstreatment
n e e d st ob es t a r t e d .D op a t i e n t sn e e dt r e a t m e n tw h e n
phenylalanine concentrations in blood are >360 μmol/L or
>600 μmol/L? This paper reviews the literature on the
outcome of untreated patients with mild hyperphenylalani-
nemia to try to determine whether outcome is normal. The
paperconcludesthat thereis,infact,onlyonepaperthatcan
be used to answer this question. Therefore, the question is
whether we may rely on one paper to draw conclusions or
whethermoreresearchisnecessarytodeterminewhetherall
patients with phenylalanine concentrations >360 μmol/L or
allpatientswithphenylalanineconcentrations>600μmol/L
require treatment.
Introduction
Notwithstanding the huge number of studies in phenylke-
tonuria (PKU; MIM# 216600), questions remain on the
table. One of those questions is whether treatment of patients
with mildly increased phenylalanine (Phe) concentrations is
necessary. The question has been addressed for years (Berry
et al. 1979; Cabalska et al. 1977; Güttler 1980; Lang et al.
1989; Levy et al. 1971) but without a clear answer.
Two recent studies showed clear variation in Phe
concentration that prompted professionals to start treatment
at (van Spronsen et al. 2009, Blau et al. 2010b). Those data
show that Phe concentrations at which treatment is started
vary from some 200 to 600 μmol/L (van Spronsen et al.
2009, Blau et al. 2010b). The study of van Spronsen et al.
(2009) reveals that of the 17 centers reporting on this issue,
eight started at a Phe >360 μmol/L, whereas seven started
at Phe between 400 μmol/L and 500 μmol/L, and two at
Phe of 600 μmol/L. Blau et al. (2010b) reported a larger
group of centers (N=93). That study did not report the
precise data, but 5% of participating centers reported
starting at Phe concentrations >200 μmol/L, 37% at>
400 μmol/L, 28%at >600 μmol/L, and 24% answered
otherwise, including at >300 μmol/L,>360 μmol/L, and
between 400 and 600 μmol/L. These data clearly show a
lack of consensus, evidencing the need for at least
discussion on this issue. Issues relevant to answering this
question are
1. How is mild hyperphenylalaninemia (mHPA) defined?
2. What is the outcome of untreated patients with blood
Phe concentrations between 360 and 600 μmol/L?
3. How sure are we about these outcome data?
4. How can we explain that a specific blood Phe
concentration considered toxic in more severe degrees
of phenylalanine hydroxylase (PAH) deficiency is
nontoxic in mHPA?
5. What are the drawbacks of dietary treatment?
6. Does the decision to treat (or not to treat) change when
possibilities of treatment do?
These questions are addressed within this report with the
aim of deciding upon the issue of whether or not to treat
individuals with mHPA.
Definition mild hyperphenylalaninemia
It makes sense to define patients with mHPA as not needing
treatment. Suggested Phe concentrations to start treatment
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and 600 μmol/L (Blau et al. 2010b). In patients up to 10–
12 years of age with PKU that are treated, suggested Phe
concentrations are generally up to 360 μmol/L (van
Spronsen and Burgard 2008). Normal Phe concentrations
are up to 120 μmol/L (Blau et al. 2010a). So, if we accept
that the definition of mHPA is the group of patients with
abnormal Phe concentrations not needing treatment, this
group at least includes patients with untreated Phe concen-
trations between 120 and 360 μmol/L. The really important
question is whether individuals with untreated Phe concen-
trations between 360 and 600 μmol/L should be included in
the mHPA group.
If we define the Phe concentration at which we
determine not to start treatment, we must decide on at
least three issues: (1) How often may Phe concentrations
be above this level before we conclude that this patient
should be treated? (2) Do we take Phe concentrations
into account during infections? (3) How frequent do we
measure when patients are just being followed without
treatment? For these three issues, there is hardly any
literature to base ideas on.
When a specific Phe concentration is considered of
clinical relevance in a particular patient, it is necessary to
start treatment as soon as this concentration is reached. On
the other hand, prescribing unnecessary treatment should be
avoided. Therefore, one event of Phe concentration above
that level seems too little to start treatment. However, a
follow-up Phe above that level probably needs to be
followed by treatment. In this light, it needs also to be
considered that treatment also consists of follow-up and that
follow-up may lead to a decreased strictness again of the
treatment when Phe concentrations remain well within
target range. Discussing the issue to take Phe concentra-
tions into account when there is some short illness, we must
take into consideration that the brain probably does not care
about the condition responsible for the Phe concentration.
So, excessive Phe concentrations during illness are as
harmful to brain development as excessive Phe concen-
trations periods without illness. Without treatment, there
may be large fluctuations of Phe concentrations that may be
harmful (Arnold et al. 1998; Anastasoaie et al. 2008). Diet
may decrease the amplitude of these fluctuations to some
extent. Therefore, these periods of short illness needs to be
taken into account. It seems impossible to have a frequency
of blood sampling in infants whose Phe concentrations are
well below the level at which treatment needs to be
considered comparable to the frequency in infants in who
almost each Phe level means a direct change in treatment.
Therefore, a lower frequency of monitoring seems reason-
able in such children.
Prevention of maternal PKU necessitates keeping Phe
concentrations <360 μmol/L (Koch et al. 2010). From
experience from the USA, it is known that it is difficult to
return to a diet when they have not been on diet for years.
However, this refers to the situation of severe PKU rather
than milder forms. At the same time, for a woman with Phe
concentrations of some 500–600 μmol/L without treatment,
it may really be hard achieving Phe concentrations <360 or
even 240 μmol/L clearly before conception. Therefore,
although there is no need for girls to be treated more strictly
than boys, the consequences of lack of treatment for
maternal PKU may be important for treating girls before
they wish to bear children.
When we decide to start treatment after some time in a
child who had previous Phe concentrations below the
threshold required to start treatment but above the upper
target treatment concentration at the same time, but who
after some time has Phe values above the threshold to
required start treatment (and above the target treatment
concentration), we must consider that this might mean that
the patient required treatment from early on.
It might be questioned whether we can define mHPA
using the tolerance of Phe or the genotype rather than the
Phe concentrations in the untreated condition. Children
followed because of mHPA will consume a more or less
normal natural protein intake, so that tolerance cannot be
used. DNA mutations may give clarity about the clinical
phenotype (Guldberg et al. 1998). Therefore, when we
decide on the in vivo definition of mHPA, we can use the
DNA genotype.
The outcome of untreated patients with blood
phenylalanine concentrations between 360
and 600 μmol/L
When IQ data are discussed, the Phe range that has been
considered harmless is up to 400 μmol/L (Costello et al.
1994), 600 μmol/L (Weglage et al. 1996a; Güttler 1980;
Smith et al. 2000), 720 μmol/L (Levy et al. 1971),
900 μmol/L (Berry et al. 1979), or even 1,200 μmol/L
(Lang et al. 1989). Costello et al’s. data can be interpreted
in more than one way. It is clear that the group of six
patients with untreated Phe concentrations <400 μmol/L
had an IQ just above 100, the group of 11 patients with
concentrations between 400 and 500 μmol/L had an IQ of
0.5 standard deviations (SD) below 100, and the group of
seven patients with untreated concentrations >500 μmol/L
had an SD score of -1.1 below 100. However, if statistical
analysis had been performed, the differences probably
would have proven to be statistically insignificant due to
the small numbers and relatively large variation. Still, based
on these figures, the British Medical Research Council for
PKU in 1993 advised that patients should be treated when
Phe concentration reach 400 μmol/L (Medical Research
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since then.
When neuropsychological data are discussed, there are six
research papers on this issue. Weglage produced two articles on
this issue in 1996 and one in 2001 (Weglage et al. 1996a;
Weglage et al. 1996b; Weglage et al. 2001). All their papers
on patients with untreated Phe concentrations between 360
and 600 μmol/L showed a normal outcome with regard to
their neuropsychological data. Diamond et al. studied patients
with untreated Phe concentrations between 360 and
600 μmol/L showing abnormalities on certain executive
functions (Diamond et al. 1997). In 2005, Gassio et al. found
abnormalities on specific executive functions at Phe concen-
trations even <360 μmol/L (Gassió et al. 2005). This is in
contrast to data of Smith et al. that showed normal
neuropsychological outcome at Phe concentrations up to
600 μmol/L (Smith et al. 2000). What can we conclude from
this? First, the question is whether we can use IQ data. Even
in treated PKU, IQ is not that abnormal when patients are not
that well treated. In the past, in treated PKU, IQ was said to
be normal even at Phe concentrations <1,300 μmol/L
and <900 μmol/L (Holtzman et al. 1986; Scriver et al.
1989). At the same time, we now know that these patients—
even though having a normal IQ—had an abnormal school
career and also had neuropsychological problems. So, IQ data
may not be that helpful to determine whether or not to treat
patients with mHPA.
When we look at the neuropsychological tests, there are
some peculiar findings should be discussed. For example,
Diamond et al. (1997) showed some abnormalities at Phe
concentrations between 360 and 600 μmol/L. That means
that the higher the Phe concentrations were within this
range, the more the neuropsychological tests showed
abnormal results. However, at the same time, as a group,
these patients showed results comparable with the normal
population. The results of Smith et al. are said to be normal
(Smith et al. 2000), but they studied patients with Phe
concentrations between 100 and 600 μmol/L with a mean
of 315 μmol/L Therefore, these data cannot be used to
answer the questions presented here. Weglage et al.
reported in 1996 that there were no problems in their group
of patients with Phe concentrations between 360 and
600 μmol/L (Weglage et al. 1996a; Weglage et al. 1996b).
However, their paper of 2001 reported that in the same
group of patients, only 10 of the 28 had untreated Phe
concentrations between 360 and 600 μmol/L (Weglage et
al. 1996a; Weglage et al. 1996b; Weglage et al. 2001). In
contrast, the data of Weglage et al. (2001) only concerned
patients with untreated Phe concentrations between 360 and
600 μmol/L (Weglage et al. 2001). Data of that study
showed really normal neuropsychological outcomes. Data
from Gassio et al. showed that Phe concentrations, which
are more or less to be considered safe in treated PKU
patients (below 360 μmol/L), are not that safe, and,
therefore, at least did not support the data of Weglage et
al. (Gassió et al. 2005, Weglage et al. 2001). So, when data
on IQ cannot be used, and some of the studies reporting on
neuropsychological outcome cannot be judged that easily,
there are at least a few reasons for some uncertainty.
Therefore, the question is whether we can determine
conclusions based on the one study by Weglage et al.
(2001).
Certainty of outcome data in PKU
In the previous paragraph, we show that it is not that easy
to decide whether or not to treat a specific group of patients
based on the one (although very good) paper of Weglage et
al. (2001). Next, some examples are shown in PKU
literature showing that deciding on data of one or two
papers on important issues and which have not been
substantiated by other papers has led to incorrect treatment
strategy. There is ongoing discussion to determine the safe
Phe concentration at various ages in treated patients. In the
past, studies showed that the Phe concentration was safe
when<1,300 μmol/L (Scriver et al. 1989). Other studies
showed that the safe Phe concentrations were<900 μmol/L
(Holtzman et al. 1986). In recent years, advice on the upper
target Phe concentration during childhood decreased to 600,
480, 360, 300, or even 240 μmol/L (van Spronsen and
Burgard 2008). Another example is uncertainty as to the
age at which treatment can be stopped safely. Initially, a
large number of clinics in North America discontinued
dietary treatment during the first decade of life (Azen et al.
1991). Such ideas on the possibility of discontinuing
treatment were based on the belief that myelination, in
particular, was complete by this age and not susceptible to
damage by high Phe concentrations and that abandonment
of the diet was consequently unlikely to be harmful. In
addition, older children with poor dietary adherence did not
become obviously disabled.
Discontinuing the diet at age 10 years in Scotland
resulted in poorer performance in cognitive and motor
function tests for patients with PKU relative to their age-
matched non-PKU peers at a median age of 20 years,
although cognitive function per se did not decline (Griffiths
et al. 1995). Neuropsychological studies (Huijbregts et al.
2002, Huijbregts et al. 2003, Azen et al. 1991) showed that
the treatment at least should continue after 12 years of age.
For later age, the only thing we know for sure is that we do
not know when—or whether at al—to stop treatment.
Studies comparing results between German and French
centers showed evidence that longer treatment was impor-
tant (Burgard et al. 1997). Nowadays, centers advise
treatment for life (van Spronsen and Burgard 2008). Of
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with PKU are strongly advised not to discontinue treatment
before childbearing age has been passed.
Difference between 360 μmol/L and 360 μmol/L
Explaining that a Phe concentration>360 μmol/L is
unsafe in one patient with classical PKU and safe in
the other patient with mild PKU is hard when there is no
additional explanation for vulnerability, or the lack of it,
in specific groups of patients. There may be at least two
possible reasons for this. One might be a difference in
Phe to tyrosine ratio between these groups. At least two
publications suggest that apart from the absolute Phe
concentration, the ratio of Phe to tyrosine might be of
important additional value in explaining and interpreting
neurocognitive outcome (Luciana et al. 2001, Sharman et
al. 2010). It may be expected that in milder PAH
deficiencies not only is Phe not that high, but tyrosine
also is higher, so that the ratio is in better balance.
However, neither of these studies have paid attention to
timing of the sampling of blood to measure tyrosine
concentrations in PKU patients. Tyrosine concentrations
are known to show large diurnal variations (van Spronsen
et al. 1993, 1996). Therefore, such studies can only be
reliable when the moment of blood sampling is carefully
specified, taking the moment of intake of tyrosine enriched
amino acid mixtures into account as well.
Another explanation, suggested by studies of Arnold et
al. and Anastasoaie et al., is that the variation in the blood
Phe concentration rather than the absolute Phe concentra-
tion may be of importance for neurocognitive development
(Arnold et al. 1998; Anastasoaie et al. 2008). Due to the
fact that in mHPA the rest activity of PAH is larger, patients
with a larger amount of functional enzyme capacity will be
able to metabolize larger amounts of Phe in a way that there
is a smaller fluctuation of the blood Phe concentration.
Therefore, in mHPA, variations in Phe concentrations may
be expected to be smaller, and following the hypothesis of
Arnold et al. (1998) and Anastasoaie et al. (2008), the
smaller these variations in Phe, the better the outcome.
Drawbacks of the dietary treatment
Notwithstanding the enormous improvement in neurocog-
nitive outcome during dietary treatment, it is fair to state
that dietary treatment has its drawbacks. It may influence
growth, as there are differences in growth patterns between
various groups/countries (Verkerk et al. 1994; Hoeksma et
al. 2005;A c o s t ae ta l .1998; Schaefer et al. 1994;
Dobbelaere et al. 2003). It clearly may result in deficiencies
of, for example, long-chain unsaturated fatty acids and
vitamin B12 (Hanley et al. 1993; Hvas et al. 2006; Huemer
et al. 2008). It results in decreased bone density (Zeman et
al. 1999, Modan-Moses et al. 2007). Patients with PKU
have less self-confidence, may have some peculiar behav-
ior, have less long -asting, stable relationships, experience
anxiety and depression (Simon et al. 2008, Smith et al.
1988, Ris et al. 1994 of 1997, Pietz et al. 1997, Waisbren
and Levy 1991, Weglage et al. 1992, Hendrikx et al. 1994).
At this time, we do not know whether this is due to
stringent treatment, to little treatment, or to PKU itself.
Influence of other treatment options on the decision
to treat or not to treat
It is fair to state that the easier the treatment, the more likely
patients will be to take the treatment. This would implicate
that the possibility of treatment strategies that are less
burdensome than the stringent diet (for review, see van
Spronsen and Enns 2010) may result in an increase in
patients who are willing to be treated. However, that
assumption is not correct. When treatment really is
unnecessary with a certain treatment modality, this conclu-
sion cannot be changed just because other treatment
modalities become available.
Conclusion
At this time, we do not have enough data to prove or
deny the hypothesis that patients who—without treat-
ment—have Phe concentrations between 360 and
600 μmol/L can remain without treatment. Further
studies are therefore warranted to solve this issue. On
the one hand, we must treat when necessary, but on the
other hand, we must prevent instituting treatment when
it is unnecessary in this group of individuals, as we may
unnecessarily make them feel as if they are patients.
Treatment may not only may make life unnecessarily
difficult for those patients and their families, it may also
induce problems with, e.g., job, career, health insurance,
as well as create an unnecessarily negative balance in
the health care system.
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